Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours

• Type: Article in International Scientific Journal
• Date: 2009

Authors

Albergaria, A (Author) Other; Joana Paredes (Author) FMUP; Sousa, B (Author) Other; Milanezi, F (Author) Other; Carneiro, V (Author) Other; Bastos, J (Author) Other; Costa, S (Author) Other; Vieira, D (Author) Other; Lopes, N (Author) Other; Lam, EW (Author) Other; Lunet N (Author) FMUP; Fernando Schmitt (Author) FMUP

Journal

Title: Breast Cancer Research

Vol. 11

Final page: R40

ISSN: 1465-5411

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 127 Citations

Scopus - 134 Citations

Other information

Authenticus ID: P-003-PAQ

DOI: 10.1186/bcr2327

Abstract (EN): Introduction The expression of additional genes, other than oestrogen receptor ( ER), may be important to the hormone-responsive phenotype of breast cancer. Microarray analyses have revealed that forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA-3) are expressed in close association with ER alpha, both encoding for transcription factors with a potential involvement in the ER alpha-mediated action in breast cancer. The purpose of this study was to explore if the expression of FOXA1 and GATA-3 may provide an opportunity to stratify subsets of patients that could have better outcome, among the ER alpha-negative/spoor prognosis breast cancer group. Methods We evaluate FOXA1 and GATA-3 expression in 249 breast carcinomas by immunohistochemistry, associating it with breast cancer molecular markers, clinicopathological features and patient's survival. The clinicopathological features and immunohistochemical markers of the tumours were compared using the chi-square test and ANOVA. Disease-free survival was analysed through Kaplan-Meier survival curves and Cox regression. Results FOXA1 expression was demonstrated in 42% of invasive carcinomas, while GATA-3 was detected in 48% of the cases. FOXA1 expression was inversely associated with tumour size, Nottingham Prognostic Index, histological grade, lymph vascular invasion, lymph node stage and human epidermal growth factor receptor-2 (HER-2) overexpression, while GATA-3 expression showed inverse association with histological grade and HER-2. Both FOXA1 and GATA-3 were directly associated with ER alpha and progesterone receptor. Among FOXA1-positive tumours, 83.1% are comprised in the luminal A subtype, similar to GATA-3 where 87.7% of positive tumours were classified within this molecular subtype. In the subset of ER alpha-negative patients, those who were FOXA1-negative had a 3.61-fold increased risk of breast cancer recurrence when compared with the FOXA1-positive. Conclusions FOXA1 was a significant predictor of good outcome in breast cancer, whereas GATA-3 was an important luminal marker. The expression of FOXA1 may be used for risk stratification among ER alpha-negative patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 15